{"pub": "financialpost", "url": "https://globenewswire.com/news-release/2019/10/15/1929997/0/en/Medexus-Announces-Changes-to-Senior-Management.html", "downloaded_at": "2019-10-15 16:23:18.292794+00:00", "title": "Medexus Announces Changes to Senior Management", "language": "en", "text": "MONTREAL, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the \u201cCompany\u201d) (TSXV: MDP, OTCQB: PDDPF) today announced changes to the Company\u2019s senior management team. Effective immediately, Mr. Sylvain Chr\u00e9tien will no longer serve as the Company\u2019s President, Canadian Operations. In accordance with his employment agreement, Mr. Chr\u00e9tien is also required to resign from the Board of Directors of the Company. Also effective immediately, Mr. Beno\u00eet H\u00e9bert will be departing from his role as the Company\u2019s Vice President, Business Development & Licensing.\n\n\n\nKen d\u2019Entremont, Chief Executive Officer of the Company, commented: \u201cOn behalf of the Board of Directors and management team, we would like to thank Mr. Chr\u00e9tien and Mr. H\u00e9bert for their invaluable work, contributions and stewardship over the years and we wish them both much success in their future endeavours. Mr. Chr\u00e9tien founded Pediapharm Inc., our predecessor entity, and loyally served as President and Chief Executive Officer of Pediapharm Inc. from 2008 until 2018. We are very grateful for his many years of guidance and leadership.\u201d\n\nAbout Medexus Pharmaceuticals Inc.\n\nMedexus is a leading specialty pharmaceutical company with a strong North American commercial platform. The Company\u2019s vision is to provide the best healthcare products to healthcare professionals and patients, through our core values of Quality, Innovation, Customer Service and Teamwork. Medexus is focused on the therapeutic areas of auto-immune disease and pediatrics. The leading products are Rasuvo\u2122 and Metoject\u00ae, a unique formulation of methotrexate (auto-pen and pre-filled syringe) designed to treat rheumatoid arthritis and other auto-immune diseases; and Rupall\u2122, an innovative allergy medication with a unique mode of action.\n\nFor further information, please contact:\n\nKen d\u2019Entremont, Chief Executive Officer\n\nMedexus Pharmaceuticals Inc.\n\nTel: 905-676-0003\n\nE-mail: ken.dentremont@medexus.com\n\nRoland Boivin, Chief Financial Officer\n\nMedexus Pharmaceuticals Inc.\n\nTel: 514-762-2626 ext. 202\n\nE-mail: roland.boivin@medexus.com\n\nInvestor Relations (U.S.):\n\nCrescendo Communications, LLC\n\nTel: +1-212-671-1020\n\nE-mail: mdp@crescendo-ir.com\n\nInvestor Relations (Canada):\n\nFrank Candido\n\nDirect Financial Strategies and Communication Inc.\n\nTel: 514-969-5530\n\nE-mail: frank.candido@medexus.com\n\nNeither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.", "description": "", "authors": ["Medexus Pharmaceuticals Inc"], "top_image": "http://www.globenewswire.com/Attachment/LogoDisplay/603317?filename=603317.jpg&size=1", "published_at": "2019-10-15"}